Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for desensitization and antibody-mediated rejection after organ transplantation (RIT-DSA-T)
jRCTs031180264Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of rituximab in HLA sensitization and Antibody-mediated allograft rejection (AMR) (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Primary endpoint - desensitized cases and Primary endpoint - antibody-mediated rejection cases. Started Mar 2018; status: completed.
02
Drugs
rituximab
03
Conditions
HLA sensitizationAntibody-mediated allograft rejection (AMR)
Beyond the preview
Go deeper on jRCTs031180264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180264.